Electronic Version v1.1 Stylesheet Version v1.1

SUBMISSION TYPE:

NEW ASSIGNMENT

Release of Security Interest Recorded at Reel/Frame 24432/321, 24432/284, 24432/317, 22432/187, and 22756/549

PATENT ASSIGNMENT

CONVEYING PARTY DATA

Name	Execution Date
Leader Ventures, LLC	09/21/2011

RECEIVING PARTY DATA

Name:	Revance Therapeutics, Inc.	
Street Address:	7555 Gateway Blvd.	
City:	Newark	
State/Country:	CALIFORNIA	
Postal Code:	94560	

PROPERTY NUMBERS Total: 23

Property Type	Number
Application Number:	12669705
Application Number:	12647677
Application Number:	12647739
Application Number:	12520964
Application Number:	11816670
Application Number:	12520971
Application Number:	12159584
Application Number:	12093442
Application Number:	11816602
Application Number:	11955076
Application Number:	11954885
Application Number:	10591485
Application Number:	10591732
Application Number:	10591486

PATENT "

REEL: 027015 FRAME: 0658

Application Number:	11617551
Application Number:	11560555
Application Number:	11367642
Application Number:	11368198
Application Number:	11073307
Application Number:	11072026
Application Number:	10793138
Application Number:	10692191
Application Number:	09910432

CORRESPONDENCE DATA

 Fax Number:
 (214)981-3400

 Phone:
 214-981-3483

 Email:
 dclark@sidley.com

Correspondence will be sent to the e-mail address first; if that is unsuccessful, it will be sent

via US Mail.

Correspondent Name: Dusan Clark, Esq.
Address Line 1: Sidley Austin LLP

Address Line 2: 717 N. Harwood St., Suite 3400

Address Line 4: Dallas, TEXAS 75201

ATTORNEY DOCKET NUMBER: 52381-30040

NAME OF SUBMITTER: Dusan Clark

Total Attachments: 3

source=Revance PA Release#page1.tif source=Revance PA Release#page2.tif source=Revance PA Release#page3.tif

> PATENT REEL: 027015 FRAME: 0659

RELEASE OF PATENT SECURITY INTEREST

THIS RELEASE OF PATENT SECURITY INTEREST ("Release") is made effective as of September 21, 2011 by LEADER VENTURES, LLC, for itself and as Agent for the Lenders (the "Agent"), to REVANCE THERAPEUTICS, INC., (the "Borrower"), as follows:

WHEREAS, on May 21, 2010, the Borrower and the Agent entered into a [Patent Security Agreement ("PSA"):

WHEREAS, pursuant to said Agreement and PSA, the Borrower granted to the Agent on behalf of the Lenders, among other collateral, a continuing security interest in all of Borrower's right, title and interest, in, to and under the United States Patents listed on the attached Schedule A (the "Patents");

WHEREAS, said PSA was recorded in the United States Patent & Trademark Office on May 24, 2010 at reel/frame 24432/321, reel/frame 24432/284, reel/frame 24432/317, reel/frame 24432/187 and on May 28, 2010 at reel/frame 22756/549;

WHEREAS, Agent wishes to release its security interest in the Patents.

NOW THEREFORE, as the Borrower has satisfied its obligations under said Agreement and PSA, the Agent hereby releases, without any recourse, statement, representation and warranty, promise or undertaking whatsoever, and at the Borrower's sole cost and expense, all right, title and interest in and to the Patents, including its security interest in and lien upon the Patents.

IN WITNESS WHEREOF, the Agent has caused this Release to be executed by its duly authorized officer.

> LEADER VENTURES, LLC. as Agent

Name. Pobast W Make
Title: Manging Director

Schedule A Patents

in and	PATENT NO./		
NO.	PUBLICATION NO./	DATE ISSUED/	TILE:
	SERIAL NO.	DATE FILED	
1.	20100215591	8/26/2010	ANTIMICROBIAL PEPTIDE,
	12669705	2/3/2010	COMPOSITIONS, AND METHODS OF
The second secon	And a control of the		USE
2.	20100168023	7/1/2010	INJECTABLE BOTULINUM TOXIN
-	12647677	12/28/2009	FORMULATIONS
3.	20100166689	7/1/2010	COMPOSITIONS AND METHODS FOR
	12647739	12/28/2009	TREATING HYPERPIGMENTATION
4.	20100093639	4/15/2010	TRANSPORT MOLECULES USING
	12520964	7/14/2009	REVERSE SEQUENCE HIV-TAT
***	304000345774		POLYPEPTIDES
5.	20100021571	1/28/2010	COMPOSITIONS AND METHODS FOR
6.	11816670 20100021502	7/1/2009	TREATING ACNE
o.	12520971	1/28/2010 7/14/2009	COMPOSITIONS AND METHODS OF
	12,0203/1	//17/2009	TOPICAL APPLICATION AND TRANSDERMAL DELIVERY OF
		-	BOTULINUM TOXINS STABILIZED WITH
	- Landers		POLYPEPTIDE FRAGMENTS DERIVED
	to the state of th	-	FROM HIV-TAT
7.	20090214452	8/27/2009	ARGININE HETEROMERS FOR TOPICAL
	12159584	10/7/2008	ADMINISTRATION
8.	20090163412	6/25/2009	COMPOSITIONS AND METHODS OF
	12093442	10/7/2008	TOPICAL APPLICATION AND
		, , ,	TRANSDERMAL DELIVERY OF
			BOTULINUM TOXINS AND REDUCED
M. Miller St. And Market			NON-TOXIN PROTEINS
9.	20090087457	4/2/2009	COMPOSITIONS AND METHODS FOR
	11816602	10/6/2008	TOPICAL APPLICATION AND
			TRANSDERMAL DELIVERY OF
······································			BOTULINUM TOXINS
10.	20080233152	9/25/2008	COMPOSITIONS AND METHODS OF
	11955076	12/21/2007	TOPICAL APPLICATION AND
			TRANSDERMAL DELIVERY OF
			BOTULINUM TOXINS STABILIZED WITH
			POLYPEPTIDE FRAGMENTS DERIVED
11.	20080226551	9/18/2008	FROM HIV-TAT
11.	11954885	12/12/2007	TRANSPORT MOLECULES USING REVERSE SEQUENCE HIV-TAT
	(1190-000	12/12/2007	POLYPEPTIDES
12.	20080200373	8/21/2008	MULTI-COMPONENT BIOLOGICAL
****	10591485	11/7/2007	TRANSPORT SYSTEMS
13.	20080107690	5/8/2008	COMPOSITIONS AND METHODS FOR
	10591732	9/26/2007	TOPICAL APPLICATION AND
		. ,	TRANSDERMAL DELIVERY OF
	•	1	BOTULINUM TOXINS
14.	20080038203	2/14/2008	COMPOSITIONS AND METHODS FOR
	10591486	6/18/2007	TOPICAL DIAGNOSTIC AND

NO.	PATENT NO./ PUBLICATION NO./ SERIAL NO.	DATE ISSUED/ DATE FILED	STEPLE:
			THERAPEUTIC TRANSPORT
15.	20070265233	11/15/2007	ARGININE HETEROMERS FOR TOPICAL
	11617551	12/28/2006	ADMINISTRATION
16.	20070116724	5/24/2007	COMPOSITIONS AND METHODS OF
	11560555	11/16/2006	TOPICAL APPLICATION AND
			TRANSDERMAL DELIVERY OF
			BOTULINUM TOXINS WITH REDUCED
			NON-TOXIN PROTEINS
17.	20070077259	4/5/2007	COMPOSITIONS AND METHODS FOR
	11367642	3/3/2006	TOPICAL APPLICATION AND
			TRANSDERMAL DELIVERY OF
Para-Milladal and transcription on	- CONTRACTOR CONTRACTO		BOTULINUM TOXINS
18.	20070037252	2/15/2007	COMPOSITIONS AND METHODS FOR
	11368198	3/3/2006	TOPICAL APPLICATION AND
			TRANSDERMAL DELIVERY OF AN
	The second contribution to the second contribution of point 4 minority. Under very very conference very consequence and contribution of points.		OLIGOPEPTIDE
19.	20050239705	10/27/2005	COMPOSITIONS AND METHODS FOR
	11073307	3/3/2005	TOPICAL DIAGNOSTIC AND
-utummentum mututen	ettett i i den den de	**************************************	THERAPEUTIC TRANSPORT
20.	20050196414	9/8/2005	COMPOSITIONS AND METHODS FOR
	11072026	3/3/2005	TOPICAL APPLICATION AND
			TRANSDERMAL DELIVERY OF
	· · · · · · · · · · · · · · · · · · ·		BOTULINUM TOXINS
21.	20040220100	11/4/2004	MULTI-COMPONENT BIOLOGICAL
	10793138	3/3/2004	TRANSPORT SYSTEMS
22.	20040157921	8/12/2004	MODULATION OF ZINC LEVELS TO
MARKET LANGE TO BARRATA	10692191	10/22/2003	IMPROVE TISSUE PROPERTIES
23.	7807780	10/5/2010	MULTI-COMPONENT BIOLOGICAL
	09910432	7/20/2001	TRANSPORT SYSTEMS